-
Mashup Score: 33Using Computer Vision to Improve Endoscopic Disease Quantification in Therapeutic Clinical Trials of Ulcerative Colitis - 3 month(s) ago
Computer vision measures of endoscopic activity are more granular and sensitive to ulcerative colitis disease severity than the Mayo Endoscopic Score and may help personalize disease and therapeutic assessments.
Source: www.gastrojournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 29Using Computer Vision to Improve Endoscopic Disease Quantification in Therapeutic Clinical Trials of Ulcerative Colitis - 4 month(s) ago
Computer vision measures of endoscopic activity are more granular and sensitive to ulcerative colitis disease severity than the Mayo Endoscopic Score and may help personalize disease and therapeutic assessments.
Source: www.gastrojournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 22Evaluation of Tofacitinib in Primary Sclerosing Cholangitis and Associated Colitis: A Multicenter, Retrospective Study - 4 month(s) ago
Primary sclerosing cholangitis (PSC) is frequently associated with inflammatory bowel disease (IBD).1 The type of IBD (ulcerative colitis or Crohn’s disease) was shown to associate with PSC outcome, but a clear understanding of the pathogenetic link between colitis activity and PSC is lacking.2-4 Tofacitinib, mainly inhibiting the Janus-Kinase (JAK) 1/3 pathway, has been approved for the treatment of ulcerative colitis.5 The aim of this study was to assess the safety and efficacy of tofacitinib in patients with PSC-IBD, including liver and bowel disease outcomes.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 2Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study - 4 month(s) ago
Improvement at 12 weeks was greater with intravenous guselkumab vs placebo. Guselkumab-treated patients without a clinical response at 12 weeks benefited from additional guselkumab administered subcutaneously. Guselkumab was well tolerated.
Source: www.gastrojournal.orgCategories: General Medicine News, GastroenterologyTweet-
In the QUASAR Phase 2b Induction study in patients with moderately to severely active ulcerative #colitis (N=313), week-12 clinical response percentage was greater with guselkumab 200 mg (61.4%) and 400 mg (60.7%) versus placebo (27.6%; both P<.001) ➡️ https://t.co/RMt0INQyDs https://t.co/Pw7Q7ccYna
-
-
Mashup Score: 3Epithelially-restricted Interferon epsilon protects against colitis. - 5 month(s) ago
Type I interferon (T1IFN) signalling is crucial for maintaining intestinal homeostasis. We previously found that the novel T1IFN, IFNε, is highly expressed by epithelial cells of the female reproductive tract, where it protects against pathogens. Its function has not been studied in the intestine. We hypothesise IFNε is important in maintaining intestinal homeostasis.
Source: www.cmghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 7Bile Acid Sequestrants in Microscopic Colitis: Clinical Outcomes and Utility of Bile Acid Testing - 5 month(s) ago
Bile acid sequestrants (BAS) may be a treatment in microscopic colitis (MC), but efficacy data are limited. We evaluated the effectiveness of BAS in MC and assessed the utility of bile acid testing to predict response.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 8Real-World Experience With Tofacitinib Dose De-Escalation in Patients With Moderate and Severe Ulcerative Colitis - 6 month(s) ago
Tofacitinib is associated with sustained steroid-free remission in patients with ulcerative colitis (UC), with the lowest effective dose recommended for maintenance therapy. However, there are limited real-world data to guide decisions on the optimal maintenance regimen. We aimed to evaluate predictors and outcomes of disease activity after tofacitinib dose de-escalation in this population.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0
Thiostrepton (TST) is a natural antibiotic with pleiotropic properties. This study aimed to elucidate the therapeutic effect of TST on experimental colitis and identify its targets. The effect of TST […]
Source: www.iasp-pain.orgCategories: Latest Headlines, RheumatologyTweet-
New in PRF’s #PapersoftheWeek read an article on how #thiostrepton alleviates experimental #colitis by promoting #RORγt ubiquitination and modulating #dysbiosis. https://t.co/DQaKQQkpB0
-
-
Mashup Score: 0FDA-Determines-REMS-for-Alosetron-No-Longer-Necessary - 7 month(s) ago
The-FDA-has-determined-Risk-Evaluation-and-Mitigation-Strategies-for-the-irritable-bowel-syndrome-drug-alosetron-are-no-longer-necessary
Source: www.gastroendonews.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 1
The latest Cochrane evidence on stool transplants; where poo from a healthy person is placed into the gut of a patient to help them recover.
Source: www.evidentlycochrane.netCategories: General Medicine News, Latest HeadlinesTweet-
A @CochraneUK blog for people with bowel inflammation caused by #Cdiff infection or ulcerative #colitis: GP @rtwalton123 looks at Cochrane evidence on stool transplants; where poo from a healthy person is put into the gut of a patient to help them recover: https://t.co/SyqjRP0DZE https://t.co/1PLF8zkBLR
-
Rethinking endoscopic activity measurement using artificial intelligence for a more detailed and personalized next-generation assessment of ulcerative #colitis – CDS: the cumulative disease score ➡️ https://t.co/K2d1LRf4JR https://t.co/9f1340m7ZY